EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Study protocol of KeyPemls ‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease ( PD ) after immunotherapy ( PD ‐1/ PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy

Jia Liu iD, Minjiang Chen iD, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu iD, Mengzhao Wang

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14806 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Jia Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Med…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitor (ICI)‐based treatment regimens have become the standard of care for first‐line treatment of metastatic epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild‐type non‐small cell lung cancer (NSCLC). Nevertheless, most patients inevitably develop disease progression, and the mechanisms of resistance to first‐line immunotherapy are not clear. ICIs in combination with agents targeting other pathways may serve as second‐line therapy options. Plinabulin is a selective immunomodulating microtubule‐binding agent which inhibits the polymerization of tubulin monomers, with multiple mechanisms to inhibit tumor growth. Clinical studies have demonstrated preliminary the antitumor efficacy of this agent. Therefore, we hypothesize that a combination of plinabulin with programmed death 1 (PD‐1) inhibitor and docetaxel may result in higher efficacy and fewer side effects leading to better tolerance.

Methods

In this investigator‐initiated, single‐arm, open‐label, phase II trial, metastatic NSCLC patients who acquired resistance to first‐line immunotherapy‐based therapy will be enrolled. Participants will receive pembrolizumab 200 mg D1, plinabulin 30 mg/m 2 D1 and D8, and docetaxel 75 mg/m 2 D1 intravenously for a 21‐day cycle. The study intervention will be given until disease progression, intolerable toxicity, informed consent withdrawal or investigator decision. The primary endpoint is investigator‐based objective response rate per Response Evaluation Criteria in Solid Tumors, version 1.1. The secondary endpoints are progression‐free survival, overall survival, duration of response, and safety.

Discussion

This trial will provide evidence of the benefit and safety of pembrolizumab in combination with plinabulin and docetaxel in metastatic NSCLC patients who have been exposed and developed resistance to first‐line PD‐1/PD‐L1 inhibitor either as monotherapy or in combination with chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansDocetaxelImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPlatinumDisease ProgressionImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenClinical Trials, Phase II as TopicAntibodies, Monoclonal, HumanizedDiketopiperazines

Stichwörter der Autor:innen

immune checkpoint inhibitorsnon-small cell lung cancerpembrolizumabplinabulinsecond-line treatment

Substanzen

DocetaxelImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPlatinumB7-H1 AntigenpembrolizumabAntibodies, Monoclonal, HumanizedNPI 2358Diketopiperazines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Jia Liu, Minjiang Chen, Yan Xu

Zitieren

APA

Liu, J., Chen, M., Gao, X., Liu, X., Zhao, J., Pan, R., Zhong, W., Xu, Y., & Wang, M. (2023). Study protocol of KeyPemls ‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease ( PD ) after immunotherapy ( PD ‐1/ PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14806

Vancouver

Liu J, Chen M, Gao X, Liu X, Zhao J, Pan R, et al. Study protocol of KeyPemls ‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease ( PD ) after immunotherapy ( PD ‐1/ PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14806

BibTeX
@article{Liu2023,
  author = {Liu, Jia and Chen, Minjiang and Gao, Xiaoxing and Liu, Xiaoyan and Zhao, Jing and Pan, Ruili and Zhong, Wei and Xu, Yan and Wang, Mengzhao},
  title = {Study protocol of KeyPemls ‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease ( PD ) after immunotherapy ( PD ‐1/ PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14806}
}
Kostenlos starten →